Dr. Aqeel A. Gillani
Claim this profileGlens Falls Hospital
Studies Cancer
Studies Lung Cancer
11 reported clinical trials
26 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
p16 positive
2Lung Cancer
Stage IV
Stage III
EGFR negative
Affiliated Hospitals
Clinical Trials Aqeel A. Gillani is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
High-Dose vs Low-Dose Cisplatin with Radiation
for Head and Neck Cancer
This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This study is being done to find out if low-dose cisplatin given weekly together with radiation therapy is the same or better than high-dose cisplatin given every 3 weeks together with radiation therapy in treating patients with head and neck cancer.
Recruiting1 award Phase 2 & 335 criteria
More about Aqeel A. Gillani
Clinical Trial Related4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Aqeel A. Gillani has experience with
- Pembrolizumab
- Carboplatin
- Nivolumab
- Radiation Therapy
- Durvalumab
- Bevacizumab
Breakdown of trials Aqeel A. Gillani has run
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Aqeel A. Gillani specialize in?
Aqeel A. Gillani focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Aqeel A. Gillani currently recruiting for clinical trials?
Yes, Aqeel A. Gillani is currently recruiting for 6 clinical trials in Glens Falls New York. If you're interested in participating, you should apply.
Are there any treatments that Aqeel A. Gillani has studied deeply?
Yes, Aqeel A. Gillani has studied treatments such as Pembrolizumab, Carboplatin, Nivolumab.
What is the best way to schedule an appointment with Aqeel A. Gillani?
Apply for one of the trials that Aqeel A. Gillani is conducting.
What is the office address of Aqeel A. Gillani?
The office of Aqeel A. Gillani is located at: Glens Falls Hospital, Glens Falls, New York 12801 United States. This is the address for their practice at the Glens Falls Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.